Readoutin 14d
Exelixis — XL092
Phase 3 primary completion: Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma.
- Date
- Dec 2026
- Type
- Readout
- Indication
- Non-Clear Cell Renal Cell Carcinoma
Readoutin 14d
Phase 3 primary completion: Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma.
The weekly brief is free. Pro adds reminders 7 days and 1 day before.